Compare Vanguard Total Stock Market Index Fund ETF (VTI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Stock Market Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Total Stock Market Index Fund ETF trades at $381.95 (market cap $2.30T), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 1138.6× GeneDx Holdings Corp's market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Total Stock Market Index Fund ETF for 131 Days and GeneDx Holdings Corp for 19 Days on average.
| VTI | WGS | |
|---|---|---|
Market Cap | $2.30T | $2.02B |
Volume | 2,982,924 | 734,640 |
52-Week High | $384.30 | $167.51 |
52-Week Low | $311.68 | $34.51 |
Typical Hold Time | 131 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTI trades at $381.94, up 0.24% on the day, with a bullish technical signal from moving averages. The ETF offers broad exposure to the U.S. stock market, though key valuation ratios like P/E and P/S are not provided in the current data. Recent news highlights its role in diversified portfolios and long-term growth potential, with a dividend scheduled for late September 2026.
The outlook for VTI is supported by its low-cost, diversified structure, appealing to long-term investors. Risks include market concentration in top holdings and overall equity market volatility. Analyst sentiment is generally positive, emphasizing its suitability for retirement and growth strategies amid current economic conditions.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
